Supplemental Table 2 Correlation between integrin expression in diffuse type gastric cancer and clinico-pathological patient characteristics

Diffuse Phenotype		αvβ3			αvβ5		
		Tumor Cells	Stroma Cells	Endothelium	Tumor Cells	Stroma Cells	Endothelium
		Negative [n (%)] Positive [n (%)]	Negative [n (%)] Positive [n (%)]	Negative [n (%)] Positive [n (%)]	Negative [n (%)] Positive [n (%)]	Negative [n (%)] Positive [n (%)]	Negative [n (%)] Positive [n (%)]
Gender	n p	144 1.000	144 1.000	144 0.854	140 1.000	141 0.360	33 0.686
Men		50 (82.0) 11 (18.0)	34 (55.7) 27 (44.3)	17 (27.9) 44 (72.1)	36 (61.0) 23 (39.0)	48 (80.0) 12 (20.0)	7 (30.4) 16 (69.6)
Women		68 (81.9) 15 (18.1)	46 (55.4) 37 (44.6)	25 (30.1) 58 (69.9)	49 (60.5) 32 (39.5)	70 (86.4) 11 (13.6)	2 (20.0) 8 (80.0)
Localization	n p	144 0.750	144 1.000	144 0.589	140 0.458	141 0.198	33 1.000
Proximal stomach		15 (78.9) 4 (21.1)	11 (57.9) 8 (42.1)	4 (21.1) 15 (78.9)	10 (52.6) 9 (47.4)	14 (73.7) 5 (26.3)	3 (30.0) 57 (70.0)
Distal stomach		103 (82.4) 22 (17.6)	69 (55.2) 56 (44.8)	38 (30.4) 87 (69.6)	75 (62.0) 46 (38.0)	104 (85.2) 18 (14.8)	6 (26.1) 17 (73.9)
pT-category	n p	144 0.432	144 0.501	144 0.474	140 0.539	141 0.265	33 0.524
pT1a		6 (85.7) 1 (14.3)	3 (42.9) 4 (57.1)	1 (14.3) 6 (85.7)	2 (66.7) 1 (33.3)	4 (100.0) 0 (0.0)	0 (0.00) 0 (0.00)
pT1b		4 (80.0) 1 (20.0)	1 (20.0) 4 (80.0)	1 (20.0) 4 (80.0)	2 (33.3) 4 (66.7)	5 (83.3) 1 (16.7)	0 (0.00) 0 (0.00)
pT2		12 (100) 0 (0.00)	6 (50.0) 6 (50.0)	3 (25.0) 9 (75.0)	7 (63.6) 4 (36.4)	9 (81.8) 2 (18.2)	2 (33.3) 4 (66.7)
pT3		45 (83.3) 9 (16.7)	30 (55.6) 24 (44.4)	13 (24.1) 41 (75.9)	30 (55.6) 24 (44.4)	44 (81.5) 10 (18.5)	5 (31.3) 11 (68.7)
pT4a		35 (74.5) 12 (25.5)	27 (57.4) 20 (42.6)	15 (31.9) 32 (68.1)	30 (63.8) 17 (36.2)	37 (78.7) 10 (21.3)	1 (11.1) 8 (88.9)
pT4b		16 (84.2) 3 (15.8)	13 (68.4) 6 (31.6)	9 (47.4) 10 (52.6)	14 (73.7) 5 (26.3)	19 (100) 0 (0.00)	1 (50.0) 8 (50.0)
pN-category	n p	142 0.630	142 0.283	142 0.617	138 0.266	139 0.832	31 0.368
pN0		27 (87.1) 4 (22.9)	14 (45.2) 17 (54.8)	7 (22.6) 24 (77.4)	13 (43.3) 17 (56.7)	23 (76.7) 7 (23.3)	1 (10.0) 9 (90.0)
pN1		19 (86.4) 3 (13.6)	14 (63.6) 8 (36.4)	7 (31.8) 15 (68.2)	16 (76.2) 5 (23.8)	20 (90.9) 2 (9.1)	1 (16.7) 5 (83.3)
pN2		18 (72.0) 7 (28.0)	13 (52.0) 12 (48.0)	8 (32.0) 17 (68.0)	17 (70.8) 7 (29.2)	21 (87.5) 3 (12.5)	3 (42.9) 4 (57.1)
pN3 (a/b)		52 (81.3) 12 (18.7)	37 (57.8) 27 (42.2)	19 (29.7) 45 (70.3)	37 (58.7) 26 (41.3)	52 (82.5) 11 (17.5)	3 (37.5) 5 (62.5)
Stage (UICC)	n p	144 0.654	144 0.420	144 0.473	140 0.803	141 0.492	30 0.569
IA		8 (80.0) 2 (20.0)	3 (30.0) 7 (70.0)	2 (20.0) 8 (80.0)	4 (44.4) 5 (56.6)	8 (88.9) 1 (11.1)	0 (0.00) 0 (0.00)
IB		6 (100) 0 (0.00)	3 (50.0) 3 (50.0)	0 (0.00) 6 (100)	2 (40.0) 3 (60.0)	4 (66.7) 2 (33.3)	1 (33.3) 2 (66.7)
IIA		13 (92.9) 1 (7.1)	8 (57.1) 6 (42.9)	5 (35.7) 9 (64.3)	7 (54.8) 6 (46.2)	11 (84.6) 2 (15.4)	0 (0.00) 5 (100)
IIB		11 (50.0) 11 (50.0)	8 (50.0) 8 (50.0)	2 (12.5) 14 (87.5)	10 (66.7) 5 (33.3)	11 (73.3) 4 (26.7)	2 (33.3) 4 (66.7)
IIIA		9 (75.0) 3 (25.0)	6 (50.0) 6 (50.0)	3 (25.0) 9 (75.0)	7 (58.3) 5 (41.7)	11 (91.7) 1 (8.3)	1 (33.3) 2 (66.7)
IIIB		23 (85.2) 4 (14.8)	15 (55.6) 12 (44.4)	9 (33.3) 18 (66.7)	16 (57.1) 12 (42.9)	21 (75.0) 7 (25.0)	3 (60.0) 2 (30.0)
IIIC		19 (70.4) 8 (29.4)	20 (74.1) 7 (25.9)	10 (37.0) 17 (63.0)	19 (70.4) 8 (29.6)	24 (88.9) 3 (11.1)	1 (33.3) 2 (66.7)
IV		26 (81.3) 6 (18.7)	17 (53.1) 15 (46.9)	11 (34.4) 21 (65.6)	20 (64.5) 11 (35.5)	28 (90.3) 3 (9.7)	1 (20.0) 4 (80.0)
"Kiel"-Stage	n p	144 0.641	144 0.413	144 0.633	140 0.288	141 0.299	33 0.141
I		8 (80.0) 2 (20.0)	3 (30.0) 7 (70.0)	2 (20.0) 8 (80.0)	4 (44.4) 5 (56.6)	8 (88.9) 1 (11.1)	0 (0.00) 0 (0.00)
II		17 (89.5) 2 (10.5)	9 (47.4) 10 (52.6)	3 (15.8) 16 (84.2)	8 (42.1) 11(57.9)	13 (68.4) 6 (31.6)	1 (11.1) 8 (88.9)
IIIA		14 (93.3) 1 (6.7)	9 (60.0) 6 (40.0)	4 (26.7) 11 (73.3)	10 (71.4) 4 (28.6)	13 (86.7) 2 (13.3)	1 (14.3) 6 (85.7)
IIIB		35 (81.4) 8 (18.6)	24 (55.8) 19 (44.2)	14 (32.6) 29 (67.4)	26 (61.9) 16 (38.1)	34 (81.0) 8 (19.0)	6 (54.5) 5 (45.5)
IV		44 (77.2) 13 (22.8)	35 (61.4) 22 (38.6)	19 (33.3) 38 (66.7)	37 (66.1) 19 (33.9)	50 (89.3) 6 (10.7)	1 (14.3) 6 (85.7)
Lymphatic invasion	n p	140 0.076	140 0.865	140 0.714	136 1.00	137 0.649	32 0.132
pL0		56 (88.9) 7 (11.1)	34 (53.9) 29 (46.1)	20 (31.7) 43 (68.3)	36 (60.0) 24 (40.0)	52 (85.2) 9 (14.8)	3 (16.7) 15 (83.3)
pL1		59 (76.6) 18 (23.4)	43 (55.8) 34 (44.2)	22 (28.6) 55 (71.4)	46 (60.5) 30 (39.5)	62 (81.6) 14 (18.4)	6 (42.9) 8 (57.1)
Venous invasion	n p	140 0.152	140 1.000	140 1.000	136 0.741	137 0.175	32 0.073
pV0		110 (83.3) 22 (16.7)	73 (55.3) 59 (44.7)	40 (30.3) 92 (69.7)	77 (60.6) 50 (39.4)	108 (84.4) 20 (15.6)	7 (23.3) 23 (76.7)
pV1		5 (62.5) 3 (37.5)	4 (50.0) 4 (50.0)	2 (25.0) 6 (75.0)	5 (55.6) 4 (44.4)	6 (66.7) 3 (33.3)	2 (100) 0 (0.00)
Tumor grade	n p	141 1.000	141 1.000	141 1.000	137 0.564	138 1.000	32 n. c.
G1 / G2		2 (100) 0 (0.00)	1 (50.0) 1 (50.0)	0 (0.00) 2 (100)	1 (33.3) 2 (66.7)	3 (100) 0 (0.00)	0 (0.00) 0 (0.00)
G3 / G4		113 (81.3) 26 (18.7)	77 (55.4) 62 (44.6)	40 (28.8) 99 (71.2)	81 (60.4) 53 (39.6)	112 (83.0) 23 (17.0)	9 (28.1) 23 (71.9)
Survival	n p	138 0.731	138 0.519	138 0.435	134 0.539	135 0.229	126 0.928
median ± SD		12.9 ± 1.9 17.5 ± 10.5	12.5 ± 2.3 15.5 ± 6.1	11.8 ± 1.9 15.5 ± 2.6	12.8 ± 3.3 14.2 ± 2.1	14.2 ± 1.9 10.6 ± 7.8	17.1 ± 4.6 14.1 ± 2.2
[95%CI]		[9.2-16.7] [0.0-38.1]	[8.4-17.3] [10.7-18.6]	[7.9-15.5] [10.5-20.5]	[6.3-19.4] [10.1-18.2]	[10.4-17.9] [0.0-25.8]	[8.0-26.1] [9.7-18.5]

"n" detones numbers of patients. "p" denotes p-value. "SD" denotes standard deviation.